92 related articles for article (PubMed ID: 32867645)
21. Ligand and Structure-based Virtual Screening of Lamiaceae Diterpenes with Potential Activity against a Novel Coronavirus (2019-nCoV).
Rodrigues GCS; Dos Santos Maia M; de Menezes RPB; Cavalcanti ABS; de Sousa NF; de Moura ÉP; Monteiro AFM; Scotti L; Scotti MT
Curr Top Med Chem; 2020; 20(24):2126-2145. PubMed ID: 32674732
[TBL] [Abstract][Full Text] [Related]
22. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
F1000Res; 2020; 9():576. PubMed ID: 32802318
[No Abstract] [Full Text] [Related]
23. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
24. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
Aftab SO; Ghouri MZ; Masood MU; Haider Z; Khan Z; Ahmad A; Munawar N
J Transl Med; 2020 Jul; 18(1):275. PubMed ID: 32635935
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.
Kadioglu O; Saeed M; Greten HJ; Efferth T
Comput Biol Med; 2021 Jun; 133():104359. PubMed ID: 33845270
[TBL] [Abstract][Full Text] [Related]
26. Natural Products Database Screening for the Discovery of Naturally Occurring SARS-Cov-2 Spike Glycoprotein Blockers.
Al-Sehemi AG; Olotu FA; Dev S; Pannipara M; Soliman ME; Carradori S; Mathew B
ChemistrySelect; 2020 Nov; 5(42):13309-13317. PubMed ID: 33363254
[TBL] [Abstract][Full Text] [Related]
27. Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses.
Negru PA; Miculas DC; Behl T; Bungau AF; Marin RC; Bungau SG
Biomed Pharmacother; 2022 Sep; 153():113432. PubMed ID: 36076487
[TBL] [Abstract][Full Text] [Related]
28. Natural products may interfere with SARS-CoV-2 attachment to the host cell.
Elfiky AA
J Biomol Struct Dyn; 2021 Jun; 39(9):3194-3203. PubMed ID: 32340551
[TBL] [Abstract][Full Text] [Related]
29. A community effort in SARS-CoV-2 drug discovery.
Schimunek J; Seidl P; Elez K; Hempel T; Le T; Noé F; Olsson S; Raich L; Winter R; Gokcan H; Gusev F; Gutkin EM; Isayev O; Kurnikova MG; Narangoda CH; Zubatyuk R; Bosko IP; Furs KV; Karpenko AD; Kornoushenko YV; Shuldau M; Yushkevich A; Benabderrahmane MB; Bousquet-Melou P; Bureau R; Charton B; Cirou BC; Gil G; Allen WJ; Sirimulla S; Watowich S; Antonopoulos N; Epitropakis N; Krasoulis A; Itsikalis V; Theodorakis S; Kozlovskii I; Maliutin A; Medvedev A; Popov P; Zaretckii M; Eghbal-Zadeh H; Halmich C; Hochreiter S; Mayr A; Ruch P; Widrich M; Berenger F; Kumar A; Yamanishi Y; Zhang KYJ; Bengio E; Bengio Y; Jain MJ; Korablyov M; Liu CH; Marcou G; Glaab E; Barnsley K; Iyengar SM; Ondrechen MJ; Haupt VJ; Kaiser F; Schroeder M; Pugliese L; Albani S; Athanasiou C; Beccari A; Carloni P; D'Arrigo G; Gianquinto E; Goßen J; Hanke A; Joseph BP; Kokh DB; Kovachka S; Manelfi C; Mukherjee G; Muñiz-Chicharro A; Musiani F; Nunes-Alves A; Paiardi G; Rossetti G; Sadiq SK; Spyrakis F; Talarico C; Tsengenes A; Wade RC; Copeland C; Gaiser J; Olson DR; Roy A; Venkatraman V; Wheeler TJ; Arthanari H; Blaschitz K; Cespugli M; Durmaz V; Fackeldey K; Fischer PD; Gorgulla C; Gruber C; Gruber K; Hetmann M; Kinney JE; Padmanabha Das KM; Pandita S; Singh A; Steinkellner G; Tesseyre G; Wagner G; Wang ZF; Yust RJ; Druzhilovskiy DS; Filimonov DA; Pogodin PV; Poroikov V; Rudik AV; Stolbov LA; Veselovsky AV; De Rosa M; De Simone G; Gulotta MR; Lombino J; Mekni N; Perricone U; Casini A; Embree A; Gordon DB; Lei D; Pratt K; Voigt CA; Chen KY; Jacob Y; Krischuns T; Lafaye P; Zettor A; Rodríguez ML; White KM; Fearon D; Von Delft F; Walsh MA; Horvath D; Brooks CL; Falsafi B; Ford B; García-Sastre A; Yup Lee S; Naffakh N; Varnek A; Klambauer G; Hermans TM
Mol Inform; 2024 Jan; 43(1):e202300262. PubMed ID: 37833243
[TBL] [Abstract][Full Text] [Related]
30. Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery.
Mohebbi A; Askari FS; Sammak AS; Ebrahimi M; Najafimemar Z
Future Virol; 2021 May; ():. PubMed ID: 34099962
[No Abstract] [Full Text] [Related]
31. MEDIATE - Molecular DockIng at homE: Turning collaborative simulations into therapeutic solutions.
Vistoli G; Manelfi C; Talarico C; Fava A; Warshel A; Tetko IV; Apostolov R; Ye Y; Latini C; Ficarelli F; Palermo G; Gadioli D; Vitali E; Varriale G; Pisapia V; Scaturro M; Coletti S; Gregori D; Gruffat D; Leija E; Hessenauer S; Delbianco A; Allegretti M; Beccari AR
Expert Opin Drug Discov; 2023; 18(8):821-833. PubMed ID: 37424369
[TBL] [Abstract][Full Text] [Related]
32. The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.
Tomić D; Davidović D; Szasz AM; Rezeli M; Pirkić B; Petrik J; Vrca VB; Janđel V; Lipić T; Skala K; Mesarić J; Periša MM; Šojat Z; Rogina BM
Inform Med Unlocked; 2021; 23():100529. PubMed ID: 33553571
[TBL] [Abstract][Full Text] [Related]
33. Computational and Experimental Approaches Identify Beta-Blockers as Potential SARS-CoV-2 Spike Inhibitors.
Puhl AC; Mottin M; Sacramento CQ; Tavella TA; Dias GG; Fintelman-Rodrigues N; Temerozo JR; Dias SSG; Ramos PRPDS; Merten EM; Pearce KH; Costa FTM; Premkumar L; Souza TML; Andrade CH; Ekins S
ACS Omega; 2022 Aug; 7(32):27950-27958. PubMed ID: 35983371
[TBL] [Abstract][Full Text] [Related]
34. High content screening strategies for large-scale compound libraries with a focus on high-containment viruses.
Subramani C; Sharma G; Chaira T; Barman TK
Antiviral Res; 2024 Jan; 221():105764. PubMed ID: 38008193
[TBL] [Abstract][Full Text] [Related]
35. African and Asian Medicinal Plants as a Repository for Prospective Antiviral Metabolites Against HIV-1 and SARS CoV-2: A Mini Review.
Anywar G; Akram M; Chishti MA
Front Pharmacol; 2021; 12():703837. PubMed ID: 34512337
[No Abstract] [Full Text] [Related]
36. Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2.
Huang R; Xu M; Zhu H; Chen CZ; Lee EM; He S; Shamim K; Bougie D; Huang W; Hall MD; Lo D; Simeonov A; Austin CP; Qiu X; Tang H; Zheng W
bioRxiv; 2020 Jul; ():. PubMed ID: 32766591
[TBL] [Abstract][Full Text] [Related]
37. DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods.
Rohani N; Ahmadi Moughari F; Eslahchi C
PeerJ; 2021; 9():e10505. PubMed ID: 33680575
[TBL] [Abstract][Full Text] [Related]
38. Identification of inhibitors against SARS-CoV-2 variants of concern using virtual screening and metadynamics-based enhanced sampling.
Mandal N; Rath SL
Chem Phys; 2023 Sep; 573():111995. PubMed ID: 37342284
[TBL] [Abstract][Full Text] [Related]
39. Natural Products as Potential Lead Compounds for Drug Discovery Against SARS-CoV-2.
Ebob OT; Babiaka SB; Ntie-Kang F
Nat Prod Bioprospect; 2021 Dec; 11(6):611-628. PubMed ID: 34515981
[TBL] [Abstract][Full Text] [Related]
40. Potential of germanium-based compounds in coronavirus infection.
Narokha V; Nizhenkovska I; Kuznetsova O
Acta Pharm; 2022 Jun; 72(2):245-258. PubMed ID: 36651511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
